WELL Health Technologies Corp.
TSX:WELL.TOMedical - Care Facilities
+$0.02 today
- Market cap
- $947.00M
- Beta
- 1.33
- P/E (TTM)
- 41.6
- EPS (TTM)
- $0.11
Volume 2.80M
Average 1.62M
WELL.TO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
WELL Health Technologies Corp.TSX: WELL.TO
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q1 FY2026 research & development was CA$0, compared with CA$0 a year earlier. Trailing-twelve-month research & development was CA$0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near CA$0 or moves back toward the trailing-twelve-month quarterly average of CA$0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
CAD · from the income statement
- Latest · FY2025
- 0 CAD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 3.46M | +9.8% |
| FY2022 | 2022-12-31 | 3.15M | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How WELL.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -100.0% is the lowest of 2, against a peer median of -8.7%.
- Research & development amounts to 0.0% of revenue for WELL.TO, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.68M USD | -8.7% | -30.1% | 2.3% | |
| LTM Mar 2026 | CA$0 CAD | -100.0% | — | 0.0% | |
| LTM Jun 2026 | CA$0 CAD | — | — | 0.0% | |
| LTM Sep 2026 | CA$0 CAD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding WELL.TO) | — | -8.7% | -30.1% | 0.0% | |
Competitors are the stored peer set for WELL.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 302.32M | 569.14M | 776.05M | 919.69M | 1.4B |
| Cost of Revenue | 148.63M | 265.85M | 403.79M | 556.68M | 875.1M |
| Gross Profit | 153.7M | 303.29M | 372.27M | 363.01M | 525.08M |
| Gross Margin | 50.8% | 53.3% | 48.0% | 39.5% | 37.5% |
| Research & Development | 0 | 3.15M | 3.46M | 0 | 0 |
| Selling, General & Admin | 123.52M | 224.11M | 276.98M | 321.47M | 432.38M |
| Operating Expenses | 161.74M | 279.31M | 337.11M | 393.21M | 412.05M |
| Depreciation & Amortization | 38.71M | 55.2M | 60.77M | 72.31M | 93.76M |
| EBITDA | 21.27M | 95.07M | 101.88M | 122.52M | 206.79M |
| EBITDA Margin | 7.0% | 16.7% | 13.1% | 13.3% | 14.8% |
| Operating Income | (6.21M) | 23.31M | 35.16M | (30.2M) | 113.03M |
| Operating Margin | -2.1% | 4.1% | 4.5% | -3.3% | 8.1% |
| Interest Income | 555K | 649K | 763K | 1.27M | 1.72M |
| Interest Expense | 7.84M | 22.86M | 32.32M | 36.88M | 54.47M |
| Other Income / Expenses | (11.99M) | (5.79M) | (15.66M) | 39.19M | (107.72M) |
| Income Before Tax | (24.77M) | 17.92M | 19.5M | 8.99M | 5.31M |
| Pre-Tax Margin | -8.2% | 3.1% | 2.5% | 1.0% | 0.4% |
| Income Tax Expense | 5.92M | (1.15M) | 2.86M | (20.1M) | 846K |
| Net Income | (30.69M) | 19.07M | 82K | 32.61M | (50.21M) |
| Net Margin | -10.2% | 3.4% | 0.0% | 3.5% | -3.6% |
| EPS (Basic) | (0.16) | 0.09 | 0.00 | 0.13 | (0.03) |
| EPS (Diluted) | (0.16) | 0.09 | 0.00 | 0.13 | (0.03) |
| Weighted Avg Shares | 190.9M | 220.69M | 236.54M | 246.76M | 1.67B |
| Weighted Avg Shares (Diluted) | 190.9M | 220.69M | 236.54M | 254.65M | 1.73B |
WELL Health Technologies Corp.
TSX:WELL.TO
Intrinsic Alpha fair value
Locked
Current Price
$3.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.